

## PRESS RELEASE

---

# Solasia acquires episil oral liquid business from Camurus

**Lund, Sweden and Tokyo, Japan — 8 July 2022** — Camurus AB (NASDAQ STO: CAMX, hereinafter “Camurus”) and Solasia Pharma K.K. (TSE: 4597, hereinafter “Solasia”) today jointly announced that they have entered into an agreement in which Solasia has acquired episil® oral liquid (episil, SP-03, hereinafter “episil”), a unique and effective treatment for intra-oral pain associated with e.g. oral mucositis, from Camurus and been granted relevant IP rights.

Under the terms of the agreement, Solasia has obtained the assets and relevant worldwide licensing rights to continue developing, manufacturing and commercializing episil.

“We are pleased to announce the transfer of ownership of episil from Camurus to Solasia”, said Yoshihiro Arai, President and CEO of Solasia. “Specializing in innovative oncology treatments, episil is an important product for Solasia for which we now have secured long-term market supply”.

“Today’s agreement with Solasia secures the further development and access for patients to episil for treatment of oral mucositis”, said Fredrik Tiberg, President and CEO of Camurus. “Solasia, with its oncology and oncology supportive care focus, is well positioned to further develop episil, while allowing Camurus to focus on its core products and pipeline programs within CNS and rare diseases”, he continues.

During a transition period up to May 2024, Camurus will continue to provide certain assistance services at Solasia’s request.

### For more information

Camurus:

Fredrik Tiberg, President & CEO  
Tel. +46 (0)46 286 46 92  
[fredrik.tiberg@camurus.com](mailto:fredrik.tiberg@camurus.com)

Fredrik Joabsson, Chief Business Development Officer  
Tel. +46 (0)70 776 17 37  
[ir@camurus.com](mailto:ir@camurus.com)

Solasia:

Solasia Pharma K.K.  
Toyokazu Ohata, Public Relations and Investor Relations  
Tel. +81 3 5843 8045  
[info@solasia.co.jp](mailto:info@solasia.co.jp)

### About episil

*episil uses the patented FluidCrysta® topical bioadhesive technology from Camurus AB, Sweden. It is a lipid-based, preservative-free liquid that adhere to the oral mucosa. Clinically demonstrated, episil has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours.<sup>1</sup> It provides physical protection to the oral sensitive and ulcerated epithelium. episil is the only ready-to-use, pocket-sized medical device that manages and relieves oral mucositis, expected helping patients suffering from oral pain to improve the quality of life (QOL). episil was first registered in Europe in 2009 and is now launched in the United States, Europe, Japan and other countries. episil oral liquid is registered as Class I medical device in Europe, 510(k) medical device in the United States, and approved as Class II medical device in Japan, China and South Korea.*

### About Camurus

*Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic*

conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).

#### **About Solasia**

Solasia is a specialty pharmaceutical company based in Asia, with a mission to provide "Better Medicine for a Brighter Tomorrow." To address the unmet medical needs in the oncology field, Solasia develops innovative medicines to contribute to the better health and brighter future of patients. For more information, visit <https://solasia.co.jp/en/>.

#### **References**

1. Hadjieva, T., et al. Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. *Support Care Cancer*. 2014, 22:1557-62.

This information was submitted for publication at 8:30 am CET on 8 July 2022.